scispace - formally typeset
Search or ask a question
Journal ArticleDOI

Ability of King's College Criteria and Model for End-Stage Liver Disease Scores to Predict Mortality of Patients With Acute Liver Failure: A Meta-analysis

01 Apr 2016-Clinical Gastroenterology and Hepatology (Clin Gastroenterol Hepatol)-Vol. 14, Iss: 4, pp 516-525
TL;DR: Based on a meta-analysis of studies, the KCC more accurately predicts hospital mortality among patients with AALF, whereas MELD scores more accurately predict mortalityamong patients with NAALF.
About: This article is published in Clinical Gastroenterology and Hepatology.The article was published on 2016-04-01 and is currently open access. It has received 91 citations till now. The article focuses on the topics: King's College Criteria & Model for End-Stage Liver Disease.

Summary (2 min read)

Jump to: [INTRODUCTION][METHODS][NAALF).][RESULTS][DISCUSSION] and [OLT.]

INTRODUCTION

  • Acute Liver Failure (ALF) is a rare, but devastating illness with a high risk of progression to multi-organ failure and death1-3.
  • The key clinical issue remains to accurately identify patients with ALF who will die without ELT, and those who will survive with medical management alone.
  • One particularly salient difference is the treatment of transplanted patients.
  • To date, there have been three meta-analyses23 of the performance of the KCC in ALF.
  • The first included only Acetaminophen-induced ALF (AALF) identifying nine studies in total, and concluded that the KCC had limited sensitivity13.

METHODS

  • All potential articles were assessed independently by two researchers (HF, MM) according to prospectively defined eligibility criteria, and disagreements were resolved by consensus or consultation with a third author (WB).
  • If this was not possible or there was doubt over the 2 x 2 calculation, the study was excluded from the subsequent analysis.
  • The DerSimonian-Laird random effects method was used to produce summary estimates of sensitivity, specificity, likelihood ratios (LR) and diagnostic odds ratio (DOR, defined as the ratio of positive to negative likelihood ratios).

NAALF).

  • A funnel plot and effective sample size (ESS) regression analysis (the logarithm of the DOR plotted against 1/√ESS) was used to investigate publication bias.
  • Data analyses were performed using the freeware Meta-Disc version 1.4 (Universidad Complutense, Madrid, Spain) and Eggers statistic calculated in Excel (Microsoft Corporation, Redmond WA)33.

RESULTS

  • The search strategy identified 4,063 potentially relevant studies.
  • Subgroup analysis was performed to assess differences in heterogeneity and diagnostic accuracy between the groups specified earlier.
  • Furthermore Egger's statistic was not significant again suggesting publication bias was not present.

DISCUSSION

  • This meta-analysis confirms that when comparing KCC and MELD for outcome prediction in ALF KCC have lower sensitivity and MELD lower specificity.
  • The sROC analysis is therefore a more valid way to pool the results of studies with varying thresholds.
  • This is no doubt a consequence of the fact that the KCC were derived from an ALF cohort, whereas MELD was developed from results in chronic liver disease patients undergoing TIPS.
  • This may be why KCC is preferred in countries facing such organ shortages and with high rates of AALF.
  • Clearly such delays are relatively short but in cases of fulminant hepatic failure it is clearly advantageous to use simpler bedside tests during the evolution of disease.

OLT.

  • Information on prothrombin time measurements and assay details were not available in all studies and may have contributed to heterogeneity or threshold effects.
  • The potential benefits of combining the specificity of the KCC with the sensitivity of MELD are attractive.
  • Such novel methods would require data for each patient rather than summative as presented for publication.
  • Many new biomarkers have been proposed in ALF but have failed to be validated in larger studies or are deemed not ready for widespread distribution.
  • Neither KCC nor MELD are optimal in all circumstances so there remains an urgent need for more accurate outcome prediction systems in ALF.

Did you find this useful? Give us your feedback

Citations
More filters
Journal ArticleDOI
TL;DR: In this article, the authors analyzed parameters of iron metabolism in a multicenter cohort of adult patients with acute liver failure (ALF) and in an acetaminophen (APAP)-induced ALF mouse model.

13 citations


Additional excerpts

  • ...The Model for End-Stage Liver Disease (MELD) and King ́s College Criteria are both commonly used prognostic models.(3-5) In addition, the U....

    [...]

Journal ArticleDOI
TL;DR: It is demonstrated that specific regeneration‐linked miRNAs discriminate outcomes in both clinical scenarios and is a potentially novel biomarker to predict outcome and optimize patient selection for liver transplantation in both acute and chronic liver disease.

12 citations


Cites background from "Ability of King's College Criteria ..."

  • ...Age, years 58 (30-70) 58 (41-80) 59 (43-65)...

    [...]

  • ...LITU admission to death, days — — 29 (10-49)...

    [...]

  • ...Bilirubin, μmol/L 86 (42-106) 79 (32-96) 72....

    [...]

  • ...These prognostic scores lack sensitivity and specificity.(36) Our current findings provide potential biomarkers that may allow optimal identification of these patients, thereby optimizing the use of LT, though this is subject to validation in a prospective cohort....

    [...]

  • ...MELD score 46 (32-53) 46 (34-51) 40 (36-54)...

    [...]

Journal ArticleDOI
TL;DR: In this article, the authors compared the characteristics and outcomes of drug-induced liver injury (DILI) caused by paracetamol and non-paracetamols medications, particularly herbal and dietary supplements.
Abstract: Objective To compare the characteristics and outcomes of drug-induced liver injury (DILI) caused by paracetamol and non-paracetamol medications, particularly herbal and dietary supplements. Design Retrospective electronic medical record data analysis. Setting, participants Adults admitted with DILI to the Gastroenterology and Liver Centre at the Royal Prince Alfred Hospital, Sydney (a quaternary referral liver transplantation centre), 2009-2020. Main outcome measures 90-day transplant-free survival; drugs implicated as causal agents in DILI. Results A total of 115 patients with paracetamol-related DILI and 69 with non-paracetamol DILI were admitted to our centre. The most frequently implicated non-paracetamol medications were antibiotics (19, 28%), herbal and dietary supplements (15, 22%), anti-tuberculosis medications (six, 9%), and anti-cancer medications (five, 7%). The number of non-paracetamol DILI admissions was similar across the study period, but the proportion linked with herbal and dietary supplements increased from 2 of 13 (15%) during 2009-11 to 9 of 19 (47%) during 2018-20 (linear trend: P = 0.011). Despite higher median baseline model for end-stage liver disease (MELD) scores, 90-day transplant-free survival for patients with paracetamol-related DILI was higher than for patients with non-paracetamol DILI (86%; 95% CI, 79-93% v 71%; 95% CI, 60-82%) and herbal and dietary supplement-related cases (59%; 95% CI, 34-85%). MELD score was an independent predictor of poorer 90-day transplant-free survival in both paracetamol-related (per point increase: adjusted hazard ratio [aHR], 1.19; 95% CI, 1.09-3.74) and non-paracetamol DILI (aHR, 1.24; 95% CI, 1.14-1.36). Conclusion In our single centre study, the proportion of cases of people hospitalised with DILI linked with herbal and dietary supplements has increased since 2009. Ninety-day transplant-free survival for patients with non-paracetamol DILI, especially those with supplement-related DILI, is poorer than for those with paracetamol-related DILI.

11 citations

Journal ArticleDOI
04 May 2020
TL;DR: Serum Gc-globulin serum levels were decreased in children with ALF and lower in those with poor outcomes compared with survivors, and could help to identify patients at high risk for poor outcomes.
Abstract: This study aimed to analyse vitamin D-binding protein (Gc-globulin) serum levels in acute liver failure (ALF) in children in relation to disease outcomes and correlations with other known markers used to evaluate the severity of ALF. Our study included 34 children (mean age 4.87 ± 5.30 years) with ALF of different causes (metabolic, 26.47%; autoimmune, 23.53%; toxic, 20.59%; infection, 17.65%; unknown, 11.76%) and 30 children without any liver injury (mean age 6.11 ± 4.26 years). The outcome was poor in 14 patients (41.18%), including one child with liver transplantation (2.94%). Serum Gc-globulin levels were significantly lower in ALF patients compared to the control group (151.57 ± 171.8 mg/L vs. 498.63 ± 252.50 mg/L; p < 0.000001), with an optimum cut-off of 163.5 mg/L (Area Under the Curve, AUC, 0.8921; sensitivity, 76.50%; specificity, 100%). Levels were also lower in patients with poor outcomes compared to survivors (59.34 ± 33.73 mg/L vs. 216.12 ± 199.69 mg/L; p < 0.0001), with an optimum cut-off 115 mg/L (AUC, 0.7642; sensitivity, 100%; specificity, 50%). Gc-globulin serum levels were variable according to ALF aetiology, i.e., lower in metabolic, infectious, or unknown causes compared to autoimmune and toxic causes. Gc-globulin serum levels were decreased in children with ALF and lower in those with poor outcomes compared with survivors. Gc-globulin serum levels were correlated with other known parameters used to evaluate the severity of ALF and could help to identify patients at high risk for poor outcomes.

11 citations

Journal ArticleDOI
TL;DR: PET imaging with 18F-DFA can be used to visualize and quantify drug-induced acute liver injury and may provide information on the progression from liver injury to hepatic failure.
Abstract: Drug-induced liver failure is a significant indication for a liver transplant, and unexpected liver toxicity is a major reason that otherwise effective therapies are removed from the market. Various methods exist for monitoring liver injury but are often inadequate to predict liver failure. New diagnostic tools are needed. Methods: We evaluate in a preclinical model whether 18F-2-deoxy-2-fluoroarabinose (18F-DFA), a PET radiotracer that measures the ribose salvage pathway, can be used to monitor acetaminophen-induced liver injury and failure. Mice treated with vehicle, 100, 300, or 500 mg/kg acetaminophen for 7 or 21 h were imaged with 18F-FDG and 18F-DFA PET. Hepatic radiotracer accumulation was correlated to survival and percentage of nonnecrotic tissue in the liver. Mice treated with acetaminophen and vehicle or N-acetylcysteine were imaged with 18F-DFA PET. 18F-DFA accumulation was evaluated in human hepatocytes engrafted into the mouse liver. Results: We show that hepatic 18F-DFA accumulation is 49%-52% lower in mice treated with high-dose acetaminophen than in mice treated with low-dose acetaminophen or vehicle. Under these same conditions, hepatic 18F-FDG accumulation was unaffected. At 21 h after acetaminophen treatment, hepatic 18F-DFA accumulation can distinguish mice that will succumb to the liver injury from those that will survive it (6.2 vs. 9.7 signal to background, respectively). Hepatic 18F-DFA accumulation in this model provides a tomographic representation of hepatocyte density in the liver, with a R2 between hepatic 18F-DFA accumulation and percentage of nonnecrotic tissue of 0.70. PET imaging with 18F-DFA can be used to distinguish effective from ineffective resolution of acetaminophen-induced liver injury with N-acetylcysteine (15.6 vs. 6.2 signal to background, respectively). Human hepatocytes, in culture or engrafted into a mouse liver, have levels of ribose salvage activity similar to those of mouse hepatocytes. Conclusion: Our findings suggest that PET imaging with 18F-DFA can be used to visualize and quantify drug-induced acute liver injury and may provide information on the progression from liver injury to hepatic failure.

10 citations


Cites background from "Ability of King's College Criteria ..."

  • ...In particular, specifically identifying patients who will progress from acute liver injury to fulminant liver failure remains a clinical challenge (1,6,13,14)....

    [...]

References
More filters
Journal ArticleDOI
04 Sep 2003-BMJ
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Abstract: Cochrane Reviews have recently started including the quantity I 2 to help readers assess the consistency of the results of studies in meta-analyses. What does this new quantity mean, and why is assessment of heterogeneity so important to clinical practice? Systematic reviews and meta-analyses can provide convincing and reliable evidence relevant to many aspects of medicine and health care.1 Their value is especially clear when the results of the studies they include show clinically important effects of similar magnitude. However, the conclusions are less clear when the included studies have differing results. In an attempt to establish whether studies are consistent, reports of meta-analyses commonly present a statistical test of heterogeneity. The test seeks to determine whether there are genuine differences underlying the results of the studies (heterogeneity), or whether the variation in findings is compatible with chance alone (homogeneity). However, the test is susceptible to the number of trials included in the meta-analysis. We have developed a new quantity, I 2, which we believe gives a better measure of the consistency between trials in a meta-analysis. Assessment of the consistency of effects across studies is an essential part of meta-analysis. Unless we know how consistent the results of studies are, we cannot determine the generalisability of the findings of the meta-analysis. Indeed, several hierarchical systems for grading evidence state that the results of studies must be consistent or homogeneous to obtain the highest grading.2–4 Tests for heterogeneity are commonly used to decide on methods for combining studies and for concluding consistency or inconsistency of findings.5 6 But what does the test achieve in practice, and how should the resulting P values be interpreted? A test for heterogeneity examines the null hypothesis that all studies are evaluating the same effect. The usual test statistic …

45,105 citations

Journal ArticleDOI
TL;DR: The MELD scale is a reliable measure of mortality risk in patients with end‐stage liver disease and suitable for use as a disease severity index to determine organ allocation priorities in patient groups with a broader range of disease severity and etiology.

4,184 citations

Journal ArticleDOI
TL;DR: This Mayo TIPS model may predict early death following elective TIPS for either prevention of variceal rebleeding or for treatment of refractory ascites, superior to both the Child‐Pugh classification and the Child-Pugh score in predicting survival.

2,479 citations

Journal ArticleDOI
TL;DR: Data suggest that the MELD score is able to accurately predict 3-month mortality among patients with chronic liver disease on the liver waiting list and can be applied for allocation of donor livers.

2,225 citations

Journal ArticleDOI
TL;DR: The effective sample size funnel plot and associated regression test of asymmetry should be used to detect publication bias and other sample size related effects in meta-analyses of test accuracy.

2,191 citations

Related Papers (5)
Frequently Asked Questions (2)
Q1. What have the authors contributed in "Meta-analysis of king's college criteria and model for end stage liver disease to predict outcome in acute liver failure" ?

The authors assessed the accuracy of King 's College Criteria ( KCC ) versus the Model-forEnd-Stage-Liver-Disease ( MELD ) in ALF through meta-analysis of studies which report the accuracy of both tests. 

The authors hope these data help inform such decisions and future research. A worsening grade of HE can be detected at the bedside and incorporated into KCC without awaiting further biochemical analysis.